fashion -WSS

fashion

author：Wikipedia 2025-09-29 13:30:32 - browse：73679

research funding, medical devices — APStock

WASHINGTON — A federal district judge on Monday granted the Biden administration’s request to dismiss a lawsuit challenging Medicare’s new drug price negotiation program from the drug industry lobbying organization PhRMA.

The move is an early but positive sign for the Biden administration in a legal fight that could stretch for years, as a host of major drugmakers, including Merck, Bristol Myers Squibb, and Johnson & Johnson, have also filed lawsuits over the constitutionality of Medicare’s new powers. The first round of drug negotiations is ongoing, and a judge heard oral arguments in a challenge brought by AstraZeneca just last month.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

The National Infusion Center Association and the Global Colon Cancer Association are also plaintiffs in PhRMA’s lawsuit. The judge dismissed the National Infusion Center Association from the case because it did not have subject matter jurisdiction to bring the lawsuit. And because NICA was the only party to the lawsuit that resides in Texas, the judge tossed out the case in its entirety.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Congress gives doctors Medicare pay bump

entertainment

WSS

Why getting cancer drugs just got harder for rural patients

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

What to do when lifesaving products contribute to climate change

How to pay for weight loss drugs and save Medicare

Scientists unlock the key to scar

Organ aging and disease risk measured by new blood test

hotspot

fashion

Sign up for D.C. Diagnosis

hotspot

Sports medicine is finally prioritizing gender equality

RaDonda Vaught to speak at CommonSpirit event on patient safety

Alkermes shareholders re

Disappointing trial forces Pfizer to pivot on obesity medicine plans

In age of alternative facts, a scholarly course on calling out crap

Mayo Clinic plans $5B tech

How one medical school became remarkably diverse

International team creates first chimeric human

Duchenne breakthrough therapy leaves behind pioneering families

Pfizer highlights cancer drugs it thinks could reignite investor interest

hotspot

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Why getting cancer drugs just got harder for rural patients

FogPharma raises $145 million in rare Series E round

The EPA's new lead rule: How one expert crunched the numbers

Biotech companies concerned about China biosecurity crackdown

Why getting cancer drugs just got harder for rural patients

hotspot

hotspot

entertainment

knowledge